Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Ho

Showing results (51-60 of 241) with videos related to

Pageof 25
Sort By:
Bulletin of Mathematical Biology|May 17, 2005
Duration of an intermittent episode of viremiaMichele Di Mascio, Jerome K Percus, Ora E Percus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 2, 2012
Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelopeCraig S Pace, Marshall W Fordyce, David Franco, et al.
Bulletin of Mathematical Biology|April 5, 2003
The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapyJerome K Percus, Ora E Percus, Martin Markowitz, et al.
Vaccine|July 6, 2010
Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine developmentDavid Franco, Wenjing Li, Fang Qing, et al.
Journal of Virology|March 29, 2003
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivoMartin Markowitz, Michael Louie, Arlene Hurley, et al.
Nature|October 4, 2008
The changing face of HIV in ChinaLin Lu, Manhong Jia, Yanling Ma, et al.
The Lancet. Microbe|December 9, 2024
Pandemic research: the need for a paradigm shiftLin-Fa Wang, Sharon R Lewin, Nanshan Zhong, et al.
Bioorganic & Medicinal Chemistry|March 23, 2005
Synthesis and human NKT cell stimulating properties of 3-O-sulfo-alpha/beta-galactosylceramidesGuo-Wen Xing, Douglass Wu, Michael A Poles, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvantXiangming Li, Masakazu Fujio, Masakazu Imamura, et al.
Cell Reports. Medicine|August 29, 2024
Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine boosterQian Wang, Ian A Mellis, Yicheng Guo, et al.
Pageof 25

Showing results (51-60 of 241) with videos related to

Sort By:
Pageof 25
Bulletin of Mathematical Biology|May 17, 2005
Duration of an intermittent episode of viremiaMichele Di Mascio, Jerome K Percus, Ora E Percus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 2, 2012
Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelopeCraig S Pace, Marshall W Fordyce, David Franco, et al.
Bulletin of Mathematical Biology|April 5, 2003
The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapyJerome K Percus, Ora E Percus, Martin Markowitz, et al.
Vaccine|July 6, 2010
Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine developmentDavid Franco, Wenjing Li, Fang Qing, et al.
Journal of Virology|March 29, 2003
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivoMartin Markowitz, Michael Louie, Arlene Hurley, et al.
Nature|October 4, 2008
The changing face of HIV in ChinaLin Lu, Manhong Jia, Yanling Ma, et al.
The Lancet. Microbe|December 9, 2024
Pandemic research: the need for a paradigm shiftLin-Fa Wang, Sharon R Lewin, Nanshan Zhong, et al.
Bioorganic & Medicinal Chemistry|March 23, 2005
Synthesis and human NKT cell stimulating properties of 3-O-sulfo-alpha/beta-galactosylceramidesGuo-Wen Xing, Douglass Wu, Michael A Poles, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvantXiangming Li, Masakazu Fujio, Masakazu Imamura, et al.
Cell Reports. Medicine|August 29, 2024
Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine boosterQian Wang, Ian A Mellis, Yicheng Guo, et al.
Pageof 25